Dilsher Dhoot, MD, provides an overview of biosimilars in retinal diseases and discusses how he identifies patients suitable for biosimilar therapy.
Harnessing the Potential of Biosimilars in Retinal Disease Management
Dilsher Dhoot, MD, presents two cases involving DME and CRVO, that show remarkable anatomical improvement with a biosimilar comparable to those achieved with reference biologics.
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
Aurion Biotech releases positive 12-month results from phase 1/2 CLARA trial
3
Dompé's NAION program selected for FDA Commissioner’s National Priority Voucher Program
4
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy
5
.png "Optometry Times"){kind=logo}
